Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + doxorubicin + cisplatin + cytarabine
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Intraperitoneal, Intravenous
01
Overview
**cyclophosphamide + doxorubicin + cisplatin + cytarabine** is a combination chemotherapy regimen consisting of four cytotoxic agents: cyclophosphamide (an alkylating agent), doxorubicin (an anthracycline topoisomerase II inhibitor), cisplatin (a platinum-based DNA cross-linking agent), and cytarabine (an antimetabolite nucleoside analog). This combination has been primarily investigated in clinical trials for the treatment of advanced, refractory, or recurrent epithelial ovarian cancer. It is often administered in a sequential schedule where systemic intravenous cisplatin, doxorubicin, and cyclophosphamide (PAC) are followed by intraperitoneal cytarabine (Ara-C) to exploit the pharmacologic advantage of local administration and maximize tumor cell kill in the peritoneal cavity.
- Other names
- cisplatin + cyclophosphamide + cytarabine + doxorubicincisplatin + cytarabine + cyclophosphamide + doxorubicincisplatin + cytarabine + doxorubicin + cyclophosphamidecisplatin + doxorubicin + cyclophosphamide + cytarabinecisplatin + doxorubicin + cytarabine + cyclophosphamidecyclophosphamide + cisplatin + cytarabine + doxorubicincyclophosphamide + cisplatin + doxorubicin + cytarabinecyclophosphamide + cytarabine + cisplatin + doxorubicincyclophosphamide + cytarabine + doxorubicin + cisplatincyclophosphamide + doxorubicin + cytarabine + cisplatincytarabine + cisplatin + cyclophosphamide + doxorubicincytarabine + cisplatin + doxorubicin + cyclophosphamidecytarabine + cyclophosphamide + cisplatin + doxorubicincytarabine + cyclophosphamide + doxorubicin + cisplatincytarabine + doxorubicin + cisplatin + cyclophosphamidecytarabine + doxorubicin + cyclophosphamide + cisplatindoxorubicin + cisplatin + cyclophosphamide + cytarabinedoxorubicin + cisplatin + cytarabine + cyclophosphamidedoxorubicin + cyclophosphamide + cisplatin + cytarabinedoxorubicin + cyclophosphamide + cytarabine + cisplatindoxorubicin + cytarabine + cisplatin + cyclophosphamidedoxorubicin + cytarabine + cyclophosphamide + cisplatinPAC + Ara-CPAC-Ara-CPAC/Ara-C
02
Targets
TOP2A (DNA topoisomerase II)POLA1 (DNA polymerase alpha)DNA
Beyond the preview
Go deeper on cyclophosphamide + doxorubicin + cisplatin + cytarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + doxorubicin + cisplatin + cytarabine.